Seeking Alpha

Gilead (GILD -0.9%) slips a bit today after Bristol-Myers (BMY +3.2%) and Abbott (ABT +3.7%)...

Gilead (GILD -0.9%) slips a bit today after Bristol-Myers (BMY +3.2%) and Abbott (ABT +3.7%) both reported favorable study results for their HCV drugs (I,II). Deutsche Bank defends the stock , saying the results of these studies show that utilizing different drug combinations yields more effective HCV treatments, and that this data actually bodes well for GILD's 7977-based class combos, for which it expects the drug developer to yield similar results.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|